1.Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
Nienke ZWAKMAN ; Rafli VAN DE LAAR ; Toon VAN GORP ; Petra LM ZUSTERZEEL ; Marc PML SNIJDERS ; Isabel FERREIRA ; Leon FAG MASSUGER ; Roy FPM KRUITWAGEN
Journal of Gynecologic Oncology 2017;28(1):e7-
OBJECTIVE: In patients with advanced stage epithelial ovarian cancer (EOC) the volume of residual tumor after debulking is known as prognostic factor for survival. We wanted to examine the relationship between postoperative decline in serum CA125 and residual disease after cytoreductive surgery and evaluate perioperative changes in serum CA125 levels as predictor for disease-specific survival. METHODS: A retrospective study was conducted of patients with FIGO stage IIb-IV EOC treated with cytoreductive surgery, followed by chemotherapy between 1996 and 2010 in three hospitals in the Southeastern region of the Netherlands. Data were analyzed with the use of multilevel linear regression and Cox-proportional hazard regression models. RESULTS: A postoperative decline in serum CA125 level of ≥80% was associated with complete primary cytoreduction (p=0.035). Univariate analyses showed favorable associations with survival for both the degree of decline in serum CA125 and residual tumor after primary cytoreduction. In multivariate analyses the decline in serum CA125 but not the outcome of surgery remained significantly associated with better survival (HR(50%–79%)=0.52 [95% CI: 0.28–0.96] and HR(≥80%)=0.26 [95% CI: 0.13–0.54] vs. the serum CA125 decline of <50% [p<0.001]). CONCLUSION: The current study, although hampered by possible biases, suggests that the perioperative decline in serum CA125 is an early biomarker that predicts disease-specific survival in patients who underwent primary cytoreductive surgery for advanced stage EOC. If confirmed prospectively, the perioperative change in serum CA125 could be a better marker for residual tumor volume after primary cytoreductive surgery (and therewith disease-specific survival) than the surgeons’ estimation of residual tumor volume.
Bias (Epidemiology)
;
CA-125 Antigen
;
Drug Therapy
;
Humans
;
Linear Models
;
Multivariate Analysis
;
Neoplasm, Residual
;
Netherlands
;
Ovarian Neoplasms*
;
Prognosis
;
Prospective Studies
;
Retrospective Studies
2.Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: a multicenter prospective cohort study
Casper REIJNEN ; Nicole CM VISSER ; Jenneke C KASIUS ; Dorry BOLL ; Peggy M GEOMINI ; Huy NGO ; Dennis VAN HAMONT ; Brenda M PIJLMAN ; Maria Caroline VOS ; Johan BULTEN ; Marc PLM SNIJDERS ; Leon FAG MASSUGER ; Johanna MA PIJNENBORG
Journal of Gynecologic Oncology 2019;30(5):e70-
OBJECTIVES: The global obesity epidemic has great impact on the prevalence of low-grade endometrial carcinoma. The preoperative tumor serum marker cancer antigen 125 (CA-125) might contribute to improved identification of high-risk patients within this group. The study aimed to investigate the prognostic value of CA-125 in relation to established preoperative prognosticators, with a focus on identifying patients with poor outcome in low-grade endometrial carcinoma (EC) patients. METHODS: Prospective multicenter cohort study including all consecutive patients surgically treated for endometrial carcinoma in nine collaborating hospitals from September 2011 until December 2013. All preoperative histopathological diagnoses were reviewed in a blinded manner. Associations between CA-125 and clinicopathological features were determined. Univariable and multivariable analysis by Cox regression were used. Separate analyses were performed for preoperatively designated low-grade and high-grade endometrial carcinoma patients. RESULTS: A total of 333 patients were analyzed. CA-125 was associated with poor prognostic features including advanced International Federation of Gynecology and Obstetrics (FIGO) stage. In multivariable analysis, age, preoperative tumor and CA-125 were significantly associated with disease-free survival (DFS); preoperative grade, tumor type, FIGO and CA-125 were significantly associated with disease-specific survival (DSS). Low-grade EC patients with elevated CA-125 revealed a DFS of 80.6% and DSS of 87.1%, compared to 92.1% and 97.2% in low-grade EC patients with normal CA-125. CONCLUSION: Preoperative elevated CA-125 was associated with poor prognostic features and independently associated with DFS and DSS. Particularly patients with low-grade EC and elevated CA-125 represent a group with poor outcome and should be considered as high-risk endometrial carcinoma.
Biomarkers
;
CA-125 Antigen
;
Cohort Studies
;
Diagnosis
;
Disease-Free Survival
;
Endometrial Neoplasms
;
Female
;
Gynecology
;
Humans
;
Obesity
;
Obstetrics
;
Prevalence
;
Prospective Studies